Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.
Razis E, Briasoulis E, Vrettou E, Skarlos DV, Papamichael D, Kostopoulos I, Samantas E, Xanthakis I, Bobos M, Galanidi E, Bai M, Gikonti I, Koukouma A, Kafiri G, Papakostas P, Kalogeras KT, Kosmidis P, Fountzilas G. Razis E, et al. Among authors: papakostas p. BMC Cancer. 2008 Aug 13;8:234. doi: 10.1186/1471-2407-8-234. BMC Cancer. 2008. PMID: 18700047 Free PMC article.
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, Kafiri G, Papakostas P, Vrettou E, Fountzilas G. Kostopoulos I, et al. Among authors: papakostas p. BMC Cancer. 2009 Sep 24;9:339. doi: 10.1186/1471-2407-9-339. BMC Cancer. 2009. PMID: 19775480 Free PMC article.
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papakostas P, Nikitas N, Papandreou CN, Pentheroudakis G, Timotheadou E, Koutras A, Sgouros J, Bafaloukos D, Klouvas G, Economopoulos T, Syrigos KN, Fountzilas G. Pectasides D, et al. Among authors: papakostas p. BMC Cancer. 2012 Jun 29;12:271. doi: 10.1186/1471-2407-12-271. BMC Cancer. 2012. PMID: 22748098 Free PMC article. Clinical Trial.
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G. Pentheroudakis G, et al. Among authors: papakostas p. BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49. BMC Cancer. 2013. PMID: 23374602 Free PMC article.
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).
Pentheroudakis G, Kotoula V, Fountzilas E, Kouvatseas G, Basdanis G, Xanthakis I, Makatsoris T, Charalambous E, Papamichael D, Samantas E, Papakostas P, Bafaloukos D, Razis E, Christodoulou C, Varthalitis I, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: papakostas p. BMC Cancer. 2014 Feb 20;14:111. doi: 10.1186/1471-2407-14-111. BMC Cancer. 2014. PMID: 24555920 Free PMC article.
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G. Razis E, et al. Among authors: papakostas p. J Cancer Res Clin Oncol. 2014 May;140(5):737-48. doi: 10.1007/s00432-014-1626-2. Epub 2014 Mar 5. J Cancer Res Clin Oncol. 2014. PMID: 24595598
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G; Hellenic Cooperative Oncology Group (HeCOG). Koutras AK, et al. Among authors: papakostas p. Br J Cancer. 2008 Dec 2;99(11):1775-85. doi: 10.1038/sj.bjc.6604769. Epub 2008 Nov 4. Br J Cancer. 2008. PMID: 18985033 Free PMC article.
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G. Razis E, et al. Among authors: papakostas p. Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19. Breast Cancer Res Treat. 2011. PMID: 21594665 Free article.
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.
Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M. Kosmidis P, et al. Among authors: papakostas p. J Clin Oncol. 2002 Sep 1;20(17):3578-85. doi: 10.1200/JCO.2002.12.112. J Clin Oncol. 2002. PMID: 12202657 Clinical Trial.
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Fountzilas G, Christodoulou C, Tsavdaridis D, Kalogera-Fountzila A, Aravantinos G, Razis E, Kalofonos HP, Papakostas P, Karina M, Gogas H, Skarlos D. Fountzilas G, et al. Among authors: papakostas p. Cancer Invest. 2004;22(5):655-62. doi: 10.1081/cnv-200032980. Cancer Invest. 2004. PMID: 15581045 Clinical Trial.
147 results